GSTM2 and prostate carcinoma: Hypermethylation of GSTM2 has been observed in several previous prostate cancer studies3,11–13, including reports that GSTM2 hypermethylation could predict biochemical recurrence12 and that a three gene biomarker panel including GSTM2 could provide a more accurate diagnosis13.